
|Videos|April 4, 2023
Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC
Dr Jason Porter presents safety and efficacy data from a Phase 1/2 study on mobocertinib in patients with mNSCLC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
5

































